{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:41:07Z","timestamp":1768624867697,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,2,7]],"date-time":"2009-02-07T00:00:00Z","timestamp":1233964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00134-009-1430-7","type":"journal-article","created":{"date-parts":[[2009,2,7]],"date-time":"2009-02-07T06:00:47Z","timestamp":1233986447000},"page":"1271-1275","source":"Crossref","is-referenced-by-count":19,"title":["Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients"],"prefix":"10.1007","volume":"35","author":[{"given":"Christopher John","family":"Kirwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Michael","family":"Grounds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain A. M.","family":"MacPhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Philips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,7]]},"reference":[{"key":"1430_CR1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00008571-200007000-00005","volume":"10","author":"A Paulussen","year":"2000","unstructured":"Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W, Konings F, Armstrong M (2000) Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10:415\u2013424","journal-title":"Pharmacogenetics"},{"key":"1430_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","volume":"39","author":"FP Guengerich","year":"1999","unstructured":"Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1\u201317","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1430_CR3","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00008571-200112000-00006","volume":"11","author":"YS Lin","year":"2001","unstructured":"Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED, Thummel KE (2001) In vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11:781\u2013791","journal-title":"Pharmacogenetics"},{"key":"1430_CR4","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","volume":"47","author":"JC Gorski","year":"1994","unstructured":"Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643\u20131653","journal-title":"Biochem Pharmacol"},{"key":"1430_CR5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","volume":"13","author":"MD Floyd","year":"2003","unstructured":"Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595\u2013606","journal-title":"Pharmacogenetics"},{"key":"1430_CR6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0022-3565(25)22834-8","volume":"271","author":"KE Thummel","year":"1994","unstructured":"Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM et al (1994) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549\u2013556","journal-title":"J Pharmacol Exp Ther"},{"key":"1430_CR7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461\u2013470","journal-title":"Ann Intern Med"},{"key":"1430_CR8","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00134-001-1120-6","volume":"27","author":"R Bellomo","year":"2001","unstructured":"Bellomo R, Kellum J, Ronco C (2001) Acute renal failure: time for consensus. Intensive Care Med 27:1685\u20131688","journal-title":"Intensive Care Med"},{"key":"1430_CR9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1067\/mcp.2000.108506","volume":"68","author":"C Wandel","year":"2000","unstructured":"Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5\u2032-promoter region polymorphism. Clin Pharmacol Ther 68:82\u201391","journal-title":"Clin Pharmacol Ther"},{"key":"1430_CR10","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/jps.2600721107","volume":"72","author":"CL Zimmerman","year":"1983","unstructured":"Zimmerman CL, Slattery JT (1983) Maintenance-dose prediction based on a single determination of concentration: general applicability to two-compartment drugs with reference to lithium. J Pharm Sci 72:1262\u20131266","journal-title":"J Pharm Sci"},{"key":"1430_CR11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0009-9236(99)70037-8","volume":"66","author":"SE Ball","year":"1999","unstructured":"Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5\u2032 promoter region of CYP3A4. Clin Pharmacol Ther 66:288\u2013294","journal-title":"Clin Pharmacol Ther"},{"key":"1430_CR12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mol.62.1.162","volume":"62","author":"YS Lin","year":"2002","unstructured":"Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162\u2013172","journal-title":"Mol Pharmacol"},{"key":"1430_CR13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383\u2013391","journal-title":"Nat Genet"},{"key":"1430_CR14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.bjp.0704951","volume":"137","author":"C Guevin","year":"2002","unstructured":"Guevin C, Michaud J, Naud J, Leblond FA, Pichette V (2002) Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 137:1039\u20131046","journal-title":"Br J Pharmacol"},{"key":"1430_CR15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/sj.bjp.0706138","volume":"144","author":"J Michaud","year":"2005","unstructured":"Michaud J, Dube P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V (2005) Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 144:1067\u20131077","journal-title":"Br J Pharmacol"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-009-1430-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00134-009-1430-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-009-1430-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:56:32Z","timestamp":1738929392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00134-009-1430-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s00134-009-1430-7","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,7]]}}}